---
title: "Kenvue, the parent company of Tylenol, refutes U.S. regulatory agencies' opposition to labeling regarding the use of medication during pregnancy and its association with autism risk"
description: "Kenvue, the parent company of Tylenol, rebutted the U.S. regulators' demands regarding its drug labeling, stating that there is a lack of scientific basis. Kenvue pointed out in documents submitted to"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261925480.md"
published_at: "2025-10-20T16:12:34.000Z"
---

# Kenvue, the parent company of Tylenol, refutes U.S. regulatory agencies' opposition to labeling regarding the use of medication during pregnancy and its association with autism risk

> Kenvue, the parent company of Tylenol, rebutted the U.S. regulators' demands regarding its drug labeling, stating that there is a lack of scientific basis. Kenvue pointed out in documents submitted to the FDA that the citizen petition requesting label changes is illegal and procedurally improper, and provided overwhelming evidence denying the association between Tylenol and autism risk

Kenvue (KVUE.US), the parent company of the pain reliever and fever reducer Tylenol, has made the most detailed defense of its flagship product, urging U.S. regulators to reject a citizen petition requesting that Tylenol be labeled with an autism association.

In documents submitted to the U.S. Food and Drug Administration (FDA) on the 17th of this month, Kenvue stated that the request to change the drug labeling lacks scientific basis and is also legally and procedurally inappropriate, with overwhelming evidence negating any claims of risk between the over-the-counter pain and fever medication and neurodevelopmental disorders

### Related Stocks

- [KVUE.US - Kenvue](https://longbridge.com/en/quote/KVUE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Kenvue｜10-K：2025 財年營收 151 億美元超過預期 |  | [Link](https://longbridge.com/en/news/276440459.md) |
| Kenvue｜8-K：2025 財年 Q4 營收 37.8 億美元超過預期 |  | [Link](https://longbridge.com/en/news/276173539.md) |
| 研究發現，第二次懷孕會給女性的大腦帶來新的變化 | 一項由阿姆斯特丹大學醫學中心的研究人員進行的研究考察了第一次和第二次懷孕對女性大腦的影響。研究跟蹤了 110 名女性，發現第一次懷孕期間大腦的 “默認模式網絡” 發生了顯著變化，這與自我反思和理解他人有關。相比之下，第二次懷孕則顯示出與注意 | [Link](https://longbridge.com/en/news/276474265.md) |
| ZAWYA-PRESSR: Kenvue 將皮膚病學的科學研究和專業教育引入 JeddaDerm | Kenvue，最大的純消費健康公司，於 2026 年 2 月 11 日至 14 日在沙特阿拉伯吉達的 JeddaDerm 展會上展示了其皮膚科專業知識。此次活動討論了皮膚健康和護髮，包括米諾地爾的臨牀作用以及膠原蛋白儲存等創新方法。Kenv | [Link](https://longbridge.com/en/news/276003935.md) |
| 研究發現，在懷孕期間停止使用抗抑鬱藥可能會增加心理健康風險 | 一項研究顯示，許多孕婦停止服用抗抑鬱藥，增加了嚴重心理健康危機的風險。心理健康問題是美國孕婦死亡的主要原因。研究發現，18% 的女性完全停止了藥物治療，65% 的女性中斷治療超過 60 天。停止治療的女性在心理健康危機方面面臨更高的風險，尤 | [Link](https://longbridge.com/en/news/275934391.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.